Cholesterol-lowering properties of amaranth grain and oil in hamsters

被引:49
|
作者
Berger, A
Gremaud, R
Baumgartner, M
Rein, D
Monnard, I
Kratky, E
Geiger, W
Burri, J
Dionisi, F
Allan, M
Lambelet, P
机构
[1] Nestle Res Ctr, CH-1000 Lausanne 26, Switzerland
[2] Nestle PTC Orbe, CH-1350 Orbe, Switzerland
[3] Cytochroma Inc, Markham, ON L3R 8E4, Canada
关键词
absorption; amaranth; bile acid; cholesterol; hamster; synthesis;
D O I
10.1024/0300-9831.73.1.39
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Amaranth was an important ancient grain and has current nutritional potential, being high in protein, fiber, lysine, magnesium, calcium, and squalene. Limited, inconsistent evidence demonstrates amaranth grain or oil can lower cholesterol in animal models. In the present study, hamsters received hypercholesterolemic diets consisting of a control, 10 or 20% Amaranthus cruentus grain, or 2.5 or 5% crude amaranth oil for four weeks. Amaranth oil (5%) decreased total and non-high-density lipoprotein (HDL) cholesterol by 15 and 22%, respectively, compared to control. Amaranth grain (20%; providing 1.4% amaranth oil) lowered non-HDL cholesterol and raised. HDL cholesterol, Amaranth grain and oil decreased very low-density lipoprotein (VLDL) cholesterol by 21-50%; and increased fecal excretion of particular neutral sterols and the bile acid ursodeoxycholate. Amaranth oil.(5%) additionally increased the cholesterol synthesis rate, possibly due to compensatory mechanisms; and decreased hepatic cholesterol ester, indicating reduced cholesterol ester availability for VLDL secretion and consistency with reduced VLDL cholesterol. Amaranth thus affected absorption of cholesterol and bile acids, cholesterol lipoprotein distribution, hepatic cholesterol content, and cholesterol biosynthesis. Amaranth grain and oil did, not affect these pathways identically.
引用
收藏
页码:39 / 47
页数:9
相关论文
共 50 条
  • [41] Cholesterol-lowering effect of garlic
    Tanphaichitr, V
    Phaksang, K
    Pakpeankitvatana, R
    Kraisintu, K
    ATHEROSCLEROSIS, 1998, 136 : S34 - S34
  • [42] Cholesterol-lowering therapy - Response
    Matsuoka, H
    Tamai, O
    Imaizumi, T
    CIRCULATION, 1997, 96 (10) : 3801 - 3802
  • [43] RATIONALE FOR CHOLESTEROL-LOWERING STRATEGIES
    GRUNDY, SM
    FRIEDMAN, D
    CURRENT PROBLEMS IN CARDIOLOGY, 1995, 20 (05) : 288 - 357
  • [44] The new cholesterol-lowering drugs
    Coudert, Pascal
    Daulhac-Terrail, Laurence
    ACTUALITES PHARMACEUTIQUES, 2020, 59 (592): : 50 - 52
  • [45] Cholesterol-lowering therapy for smokers
    Jackson, PR
    LANCET, 2001, 357 (9260): : 960 - 960
  • [46] Probiotics Cholesterol-lowering Probiotic
    不详
    MEDIZINISCHE WELT, 2017, 68 (06): : 274 - 274
  • [47] CHOLESTEROL-LOWERING AND CORONARY VASOMOTION
    JIALAL, I
    NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (05): : 324 - 324
  • [48] CHOLESTEROL-LOWERING EFFECT OF PECTIN
    JUDD, PA
    KAY, RM
    TRUSWELL, AS
    NUTRITION AND METABOLISM, 1977, 21 : 84 - 85
  • [49] CHOLESTEROL-LOWERING AGENTS SYNTHESIZED
    BORMAN, S
    CHEMICAL & ENGINEERING NEWS, 1994, 72 (47) : 9 - 10
  • [50] Cholesterol-lowering drugs in children
    Girardet, JP
    THERAPIE, 2003, 58 (01): : 63 - 67